Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4

Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4

Metastatic medullary thyroid cancer (MTC) is a rare but often aggressive thyroid malignancy with a 5-year survival rate of less than 40% and few effective therapeutic options. Adoptive T cell immunotherapy using chimeric antigen receptor (CAR)-modified T cells (CAR Ts) is showing encouraging results...

Full description

Bibliographic Details
Main Authors: Vijay G. Bhoj, Lucy Li, Kalpana Parvathaneni, Zheng Zhang, Stephen Kacir, Dimitrios Arhontoulis, Kenneth Zhou, Bevin McGettigan-Croce, Selene Nunez-Cruz, Gayathri Gulendran, Alina C. Boesteanu, Laura Johnson, Michael D. Feldman, Enrico Radaelli, Keith Mansfield, MacLean Nasrallah, Rebecca S. Goydel, Haiyong Peng, Christoph Rader, Michael C. Milone, Don L. Siegel
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:Molecular Therapy: Oncolytics
Subjects:
Medullary thyroid carcinoma
immunotherapy
GFRa4
CAR T cells
RETMC
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770521000139

Internet

http://www.sciencedirect.com/science/article/pii/S2372770521000139

Similar Items